ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TRAX vs XERS // RETURN ON INVESTED CAPITAL (ROIC)

First Tracks Biotherapeutics Inc. (NASDAQ) VS. Xeris Biopharma Holdings Inc. (NASDAQ) • 15-METRIC TALLY: TRAX 1 — XERS 4
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: XERS
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TRAX VS. XERS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TRAX XERS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -35.00% 16.00% -51.00 XERS /roic <GO>
EV/EBITDA & P/E Valuation — 83.1x — TIE /valuation <GO>
Free Cash Flow Yield -7.53% 1.46% -8.99 XERS /fcf-yield <GO>
Operating Margin — 8.50% — TIE /operating-margins <GO>
Net Profit Margin — 0.20% — TIE /net-margins <GO>
Revenue Growth (YoY) — 43.70% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 2.11 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 7/9 -5.00 XERS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 65.8 60.0 +5.77 TRAX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.90B $1.96B -$59.7M XERS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TRAX REV XERS REV TRAX GROSS % XERS GROSS % TRAX FCF XERS FCF
FY 2025 $0 $291.8M — — -$143.0M $28.6M
FY 2024 $0 $203.1M — — -$126.2M -$37.0M
FY 2023 — $163.9M — — — -$47.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TRAX // BETA —
XERS // BETA —